Clinical research in systemic lupus erythematosus: Immediate relevance to clinical practice

International Journal of Rheumatic Diseases

Volumn 14, Issue 1, 2011, Pages 1-5

  Petri, Michelle ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Lupus nephritis; Lupus pregnancy; SLE

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANTINUCLEAR ANTIBODY; ATORVASTATIN; AZATHIOPRINE; B CELL ACTIVATING FACTOR; BELIMUMAB; CHOLESTEROL; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; CYTOKINE; DOUBLE STRANDED DNA ANTIBODY; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; LEVOTHYROXINE; LOW DENSITY LIPOPROTEIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMEGA 3 FATTY ACID; PHOSPHOLIPID ANTIBODY; PREDNISONE; PROTEIN; RITUXIMAB; THYROID ANTIBODY; TRIAMCINOLONE;

ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; BONE NECROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CATARACT; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; COGNITIVE DEFECT; CREATININE URINE LEVEL; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DRUG MEGADOSE; FRAGILITY FRACTURE; HIGH RISK PREGNANCY; HUMAN; HYPERLIPIDEMIA; KIDNEY INJURY; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; LUPUS FLARE; MYCOPHENOLATE RESPONSE; MYELITIS; NERVOUS SYSTEM INJURY; ORGAN INJURY; PREGNANCY OUTCOME; PREMATURE LABOR; PRIORITY JOURNAL; PROTEIN URINE LEVEL; REMISSION; RHEUMATOID ARTHRITIS; SIDE EFFECT; SPONTANEOUS ABORTION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; WEIGHT;

ADULT; ATHEROSCLEROSIS; BIOMEDICAL RESEARCH; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; PREDNISONE; PREGNANCY; PREGNANCY COMPLICATIONS; PROFESSIONAL PRACTICE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRANSLATIONAL RESEARCH;

EID: 79551702177     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/j.1756-185X.2010.01590.x     Document Type: Article

References (47)

1. Tan EM, Cohen AS, Fries JF, et al. (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25, 1271-7.
2. Hochberg MC (1997) Updating the American College of Rheumatology Revised Criteria for the Classification of Systemic Lupus Erythematosus. Arthritis Rheum 40, 1725.
3. Petri M, Systemic Lupus International Collaborating Clinic (SLICC) (2009) SLICC Revision of the ACR Classification Criteria for SLE [abstract]. Arthritis Rheum 60(Suppl. 10), S336.
4. Barr S, Zonana-Nacach A, Magder L, Petri M (1999) Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum 42, 2682-8.
5. Smolen JS, Aletaha D, Bijlsma JW, et al. (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69, 631-7.
6. Petri M, Lakatta C, Magder L, Goldman DW (1994) Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 96, 254-9.
7. Quatraro A, Consoli G, Magno M, et al. (1990) Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug? Ann Intern Med 112, 678-81.
8. Gladman DD, Urowitz MB, Rahman P, Ibanez D, Tam LS (2003) Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 30, 1955-9.
9. Zonana-Nacach A, Barr SG, Magder LS, Petri M (2000) Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 43, 1801-8.
10. Thamer M, Hernan MA, Zhang Y, Cotter D, Petri M (2009) Prednisone, lupus activity, and permanent organ damage. J Rheumatol 36, 560-4.
11. Canadian Hydroxychloroquine Study Group. (1991) A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 324, 150-4.
12. Fessler BJ, Alarcon GS, McGwin G Jr, et al. (2005) Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 52, 1473-80.
13. Petri M (1996) Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus 5(Suppl. 1), S16-22.
14. Wallace DJ, Metzger AL, Stecher VJ, Turnbull BA, Kern PA (1990) Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 89, 322-6.
15. Pierangeli SS, Harris EN (1996) In vivo models of thrombosis for the antiphospholipid syndrome. Lupus 5, 451-5.
16. Petri M (1996) Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand J Rheumatol 25, 191-3.
17. Alarcon GS, McGwin G, Bertoli AM, et al. (2007) Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 66, 1168-72.
18. Ruiz-Irastorza G, Egurbide MV, Pijoan JI, et al. (2006) Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 15, 577-83.
19. Kasitanon N, Fine DM, Haas M, Magder LS, Petri M (2006) Hydroxychloroquine use predicts complete renal remission within 12months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus 15, 366-70.
20. Christopher-Stine L, Petri M, Astor BC, Fine D (2004) Urine protein-to-creatinine ratio is a reliable measure of proteinuria in lupus nephritis. J Rheumatol 31, 1557-9.
21. Chan TM, Li FK, Tang CS, et al. (2000) Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 343, 1156-62.
22. Ginzler EM, Dooley MA, Aranow C, et al. (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353, 2219-28.
23. Appel GB, Contreras G, Dooley MA, et al. (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20, 1103-12.
24. Contreras G, Pardo V, Leclercq B, et al. (2004) Sequential therapies for proliferative lupus nephritis. N Engl J Med 350, 971-80.
25. Sinclair A, Appel G, Dooley MA, et al. (2007) Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). Lupus 16, 972-80.
26. Lateef A, Petri M (2010) Systemic lupus erythematosus (SLE) in pregnancy. In: Adu D, Emery P, Madaio MP (eds) Rheumatology and the Kidney, 2nd edn. Oxford University Press, Oxford (in press).
27. Mak C, Magder L, Petri M (2008) SLE pregnancy: global and organ system-specific effects on disease activity [abst.]. Arthritis Rheum 58(Suppl. 9), S803.
28. Clowse M, Magder L, Witter F, Petri M (2006) Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 54, 3640-7.
29. Stagnaro-Green A, Akhter E, Yim C, Davies TF, Magder L, Petri M (2010) Thyroid disease in pregnant women with SLE: increased preterm delivery. Lupus (in press).
30. Negro R, Formoso G, Mangieri T, Pezzarossa A, Dazzi D, Hassan H (2006) Levothyroxine treatment in euthyroid pregnant women with autoimmune thyroid disease: effects on obstetrical complications. J Clin Endocrinol Metab 91, 2587-91.
31. Birnbaum J, Petri M, Thompson R, Izbudak I, Kerr D (2009) Distinct subtypes of myelitis in systemic lupus erythematosus. Arthritis Rheum 60, 3378-87.
32. McLaurin EY, Holliday SL, Williams P, Brey RL (2005) Predictors of cognitive dysfunction in patients with systemic lupus erythematosus. Neurology 64, 297-303.
33. Naqibuddin M, Wallace DJ, Weisman MH, et al. (2005) Depression is associated with poorer cognitive function in newly diagnosed systemic lupus erythematosus patients [abst.]. Arthritis Rheum 52(Suppl. 9), S379.
34. Kowal C, Degiorgio LA, Lee JY, et al. (2006) Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc Natl Acad Sci U S A 103, 19854-9.
35. Maksimowicz-McKinnon K, Magder LS, Petri M (2006) Predictors of carotid atherosclerosis in systemic lupus erythematosus. J Rheumatol 33, 2458-63.
36. Kiani AN, Vogel-Claussen J, Magder LS, Petri M (2010) Noncalcified coronary plaque in SLE. J Rheumatol 37, 579-84.
37. Petri M, Kiani AN, Post W, Christopher-Stine L, Magder LS (2010) Lupus Atherosclerosis Prevention Study (LAPS). Ann Rheum Dis (in press).
38. Merrill JT, Neuwelt CM, Wallace DJ, et al. (2010) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62, 222-33.
39. Sanna G, Bertolaccini ML, Khamashta MA (2008) Neuropsychiatric involvement in systemic lupus erythematosus: current therapeutic approach. Curr Pharm Des 14, 1261-9.
40. Kumar S, Benseler SM, Kirby-Allen M, Silverman ED (2009) B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus. Pediatrics 123, e159-63.
41. Erkan D, Lockshin MD (2009) New approaches for managing antiphospholipid syndrome. Nat Clin Pract Rheumatol 5, 160-70.
42. Furie RA, Petri MA, Wallace DJ, et al. (2009) Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 61, 1143-51.
43. Somers E, Magder LS, Petri M (2002) Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. J Rheumatol 29, 2531-6.
44. Erkan D, Harrison MJ, Levy R, et al. (2007) Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 56, 2382-91.
45. Ginsburg KS, Liang MH, Newcomer L, et al. (1992) Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 117, 997-1002.
46. Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM (2009) Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 61, 29-36.
47. Jung H, Bobba R, Su J, et al. (2010) The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 62, 863-8.